MX2021011588A - Antagonistas del receptor muscarinico de acetilcolina subtipo 4 en el tratamiento de la anemia. - Google Patents
Antagonistas del receptor muscarinico de acetilcolina subtipo 4 en el tratamiento de la anemia.Info
- Publication number
- MX2021011588A MX2021011588A MX2021011588A MX2021011588A MX2021011588A MX 2021011588 A MX2021011588 A MX 2021011588A MX 2021011588 A MX2021011588 A MX 2021011588A MX 2021011588 A MX2021011588 A MX 2021011588A MX 2021011588 A MX2021011588 A MX 2021011588A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonists
- anemia
- treatment
- muscarinic receptor
- acetylcholine subtype
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823214P | 2019-03-25 | 2019-03-25 | |
| PCT/US2020/023989 WO2020198054A1 (en) | 2019-03-25 | 2020-03-20 | Muscarinic acetylcholine receptor subtype 4 antagonists in the treatment of anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011588A true MX2021011588A (es) | 2021-12-15 |
Family
ID=72608578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011588A MX2021011588A (es) | 2019-03-25 | 2020-03-20 | Antagonistas del receptor muscarinico de acetilcolina subtipo 4 en el tratamiento de la anemia. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12497411B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3946321A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7558187B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102914803B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113613650B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020247812B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021019189A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3132381A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL286617A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021011588A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202109857UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020198054A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113613650B (zh) | 2019-03-25 | 2024-12-10 | 冷泉港实验室 | 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3649626A (en) * | 1970-04-27 | 1972-03-14 | Warner Lambert Co | Fused ring systems containing (1 3)oxazine |
| DK1282625T3 (da) * | 2000-05-09 | 2004-11-15 | Warner Lambert Co | Anvendelsen af benzoxaziner i behandlingen af Parkinsons sygdom |
| CA2357306A1 (en) | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Fused ring system containing indole as m4 selective aza-anthracene muscarinic receptor antagonists |
| US8329689B2 (en) * | 2006-05-23 | 2012-12-11 | Alexandre Vasilievich Ivachtchenko | Substituted indoles and a method for the production and use thereof |
| US20130059783A1 (en) * | 2010-03-12 | 2013-03-07 | Johan Flygare | Compositions and methods for expanding bfu-e cells |
| EP3490542A4 (en) | 2016-07-26 | 2020-07-08 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE |
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
| CN113613650B (zh) | 2019-03-25 | 2024-12-10 | 冷泉港实验室 | 治疗贫血的毒蕈碱乙酰胆碱受体亚型4拮抗剂 |
-
2020
- 2020-03-20 CN CN202080024089.9A patent/CN113613650B/zh active Active
- 2020-03-20 JP JP2021553300A patent/JP7558187B2/ja active Active
- 2020-03-20 AU AU2020247812A patent/AU2020247812B2/en active Active
- 2020-03-20 CA CA3132381A patent/CA3132381A1/en active Pending
- 2020-03-20 KR KR1020217029823A patent/KR102914803B1/ko active Active
- 2020-03-20 SG SG11202109857U patent/SG11202109857UA/en unknown
- 2020-03-20 EP EP20776829.2A patent/EP3946321A4/en active Pending
- 2020-03-20 WO PCT/US2020/023989 patent/WO2020198054A1/en not_active Ceased
- 2020-03-20 MX MX2021011588A patent/MX2021011588A/es unknown
- 2020-03-20 BR BR112021019189A patent/BR112021019189A2/pt unknown
- 2020-03-20 US US17/442,926 patent/US12497411B2/en active Active
-
2021
- 2021-09-23 IL IL286617A patent/IL286617A/en unknown
-
2024
- 2024-05-20 JP JP2024081788A patent/JP2024102364A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202109857UA (en) | 2021-10-28 |
| IL286617A (en) | 2021-10-31 |
| KR102914803B1 (ko) | 2026-01-20 |
| CA3132381A1 (en) | 2020-10-01 |
| EP3946321A4 (en) | 2023-03-08 |
| JP2024102364A (ja) | 2024-07-30 |
| JP2022525293A (ja) | 2022-05-12 |
| CN113613650B (zh) | 2024-12-10 |
| AU2020247812B2 (en) | 2025-09-11 |
| BR112021019189A2 (pt) | 2021-11-30 |
| KR20210144697A (ko) | 2021-11-30 |
| AU2020247812A1 (en) | 2021-09-30 |
| JP7558187B2 (ja) | 2024-09-30 |
| US20220185821A1 (en) | 2022-06-16 |
| CN113613650A (zh) | 2021-11-05 |
| WO2020198054A1 (en) | 2020-10-01 |
| EP3946321A1 (en) | 2022-02-09 |
| US12497411B2 (en) | 2025-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500509A1 (en) | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | |
| SA521422031B1 (ar) | مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين | |
| CY1124519T1 (el) | ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΚΑΙ ΦΑΡΜΑΚΟΤΕΧΝΙΚΕΣ ΜΟΡΦΕΣ ΤΟΥ (S)-4-(8-ΑΜΙΝΟ-3-(1-(ΒΟΥΤ-2-ΥΝΟΫΛΟ)ΠΥΡΡΟΛΙΔΙΝ-2-ΥΛΟ) ΙΜΙΔΑΖΟ[1,5-α|ΠΥΡΑΖΙΝ-1-ΥΛΟ)-Ν-(ΠΥΡΙΔΙΝ-2-ΥΛΟ) ΒΕΝΖΑΜΙΔΙΟΥ | |
| EA201992322A3 (ru) | Соединения и композиции для лечения гематологических расстройств | |
| ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
| DE602007010781D1 (de) | N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration | |
| MX384948B (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos. | |
| BRPI0813625A2 (pt) | Imidazo-[1,2b]-piridozinas 2,3,7-substituídos para tratamento de doenças mediadas por alzk4 ou alk5 | |
| BRPI0508820A (pt) | compostos como moduladores de receptor de opióide | |
| EA201100426A1 (ru) | Бициклические ингибиторы киназы | |
| EA201071291A3 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
| GEAP202014908A (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| NZ746950A (en) | Heterocyclic gpr119 agonist compounds | |
| MX2020001979A (es) | Macrociclo que contiene aminopirazol y pirimidina y composicion farmaceutica y uso de la misma. | |
| ATE503754T1 (de) | 1h-indol-3-carbonsäure-chinuclidin-4- ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit | |
| TN2012000042A1 (en) | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhitors | |
| CL2008002689A1 (es) | Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia. | |
| TW200745004A (en) | Novel compounds, their preparation and use | |
| MX2020006754A (es) | Moduladores de molécula pequeña de pantotenato-cinasas. | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| UY37973A (es) | Derivados de indol macrocíclicos | |
| TN2018000372A1 (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions. | |
| UY37972A (es) | Derivados de indol macrocíclicos sustituidos con cloro | |
| MX2023005408A (es) | Compuestos y su uso en el tratamiento de trastornos mediados por el receptor de taquiquinina. | |
| EA201071369A1 (ru) | Композиции для лечения выпадения волос |